Hiseco announced that its subsidiary Shanghai Hiseco Pharmaceutical Technology Co., Ltd. received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration. The clinical trial applications for two new indications of HSK44459 tablets, psoriasis and atopic dermatitis, meet the relevant requirements for drug registration, and the company agrees to conduct clinical trials. HSK44459 is a drug independently developed by the company to treat psoriasis and atopic dermatitis. The results of preclinical studies show that this product has a clear target, definite efficacy, and good safety. It is a small molecule drug with great development potential, a high benefit/risk ratio in clinical applications, and has broad prospects for clinical application. It is expected to become an effective treatment for psoriasis and atopic dermatitis.